ReAlta’s goal is to protect the newborn brain—preserving function, potential, and life.
- Pegtarazimod, ReAlta’s lead compound, uniquely modifies two of the most upstream inflammatory drivers of injury and is being assessed for Hypoxic Ischemic Encephalopathy (HIE).
- HIE is a devastating neonatal condition that has remained largely unaddressed by drug development efforts, and has little to no therapeutic innovation beyond supportive care.
- With Phase 2 interim data now available, pegtarazimod represents a clinically advanced approach toward disease modification in neonatal HIE.
Late-stage clinical development across multiple inflammatory indications validates the potential of pegtarazimod
- Pegtarazimod, ReAlta’s lead compound, uniquely modifies two of the most upstream inflammatory pathways at the source: neutrophils and complement.
- This approach has produced an excellent safety profile while maximizing efficacy via early-stage inflammatory cascade inhibition in clinical trials.
- Pegtarazimod has been designed as a platform-asset (pipeline in a drug) with expansive applicability across inflammatory diseases.
